The Journal of Liquid Biopsy,
Journal Year:
2023,
Volume and Issue:
3, P. 100132 - 100132
Published: Dec. 12, 2023
Despite
a
significant
evolution
in
treatment
strategies
for
early
breast
cancer
(EBC)
patients,
up
to
30%
of
them
experience
recurrence
due
occult
micrometastasis.
The
minimal
residual
disease
(minimal
RD)
EBC
patients
after
the
with
curative
intent
cannot
be
easily
detected
by
clinical
examination
and
radiological
imaging,
as
they
are
both
burdened
limited
sensitivity.
A
new
frontier
promising
approach
address
this
unmet
need
is
study
liquid
biopsy
(LB).
most
studied
tumor-derived
analytes
peripheral
blood
RD
monitoring
currently:
i)
circulating
tumor
DNA
(ctDNA),
detection
somatic
alterations,
so
referred
molecular
(MRD);
ii)
cells
(CTCs),
cellular
(CRD).
MRD
detection,
while
reaching
high
specificity,
still
presenting
number
limitations.
On
other
hand,
CRD
allows
real-time
monitoring,
detecting
live
cells,
possess
potential
provide
an
enormous
amount
biological
information.
Indeed,
CTCs
can
multi-level
portrait
(i.e.,
DNA,
RNA
proteins)
tumor,
longitudinally
depicting
its
evolving
landscape,
used
functional
(in
vitro/in
vivo)
characterization.
Moreover,
goes
beyond
association
risk
recurrence:
predictive
biomarkers
response
also
evaluated.
Nevertheless,
less
context,
because
their
immediately
processed
small
fraction
post-surgery
setting.
These
limitations
could
however
overcome
use
newly
developed
technologies
that
enable
increased
CTC
rate
retrospective
studies.
Here,
we
review
strengths
using
focusing
on
methodologies
available
LB
analysis
setting,
main
studies
investigating
EBC.
Considering
limits
advantages
CRD,
propose
integration
ctDNA
complementary
tools
assessment
achieve
synergistic
novel
analysis.
Molecular Cancer,
Journal Year:
2023,
Volume and Issue:
22(1)
Published: Nov. 28, 2023
The
advent
of
iPSCs
has
brought
about
a
significant
transformation
in
stem
cell
research,
opening
up
promising
avenues
for
advancing
cancer
treatment.
formation
is
multifaceted
process
influenced
by
genetic,
epigenetic,
and
environmental
factors.
offer
distinctive
platform
investigating
the
origin
cancer,
paving
way
novel
approaches
to
treatment,
drug
testing,
tailored
medical
interventions.
This
review
article
will
provide
an
overview
science
behind
iPSCs,
current
limitations
challenges
iPSC-based
therapy,
ethical
social
implications,
comparative
analysis
with
other
types
also
discuss
applications
tumorigenesis,
future
tumorigenesis
highlight
successful
case
studies
utilizing
research.
conclusion
summarize
advancements
made
research
importance
continued
investment
iPSC
unlock
full
potential
these
cells.
Advanced Science,
Journal Year:
2023,
Volume and Issue:
10(32)
Published: Sept. 25, 2023
Extracellular
vesicles
(EVs),
involved
in
essential
physiological
and
pathological
processes
of
the
organism,
have
emerged
as
powerful
tools
for
disease
treatment
owing
to
their
unique
natural
biological
characteristics
artificially
acquired
advantages.
However,
limited
targeting
ability,
insufficient
production
yield,
low
drug-loading
capability
simplex
EVs
greatly
hindered
development
clinical
translation.
Therefore,
establishment
multifunctional
hybrid
membrane
nanovesicles
(HMNVs)
with
favorable
adaptability
flexibility
has
become
key
expanding
practical
application
EVs.
This
timely
review
summarizes
current
progress
HMNVs
biomedical
applications.
Different
preparation
strategies
including
physical,
chemical,
chimera
approaches
are
first
discussed.
then
individually
describes
diverse
types
based
on
homologous
or
heterologous
cell
substances,
a
fusion
liposome,
well
bacterial
membrane.
Subsequently,
specific
emphasis
is
placed
highlight
applications
toward
various
diseases
representative
examples.
Finally,
ongoing
challenges
prospects
currently
developed
translational
briefly
presented.
will
not
only
stimulate
broad
interest
among
researchers
from
disciplines
but
also
provide
valuable
insights
promising
nanoplatforms
precision
medicine.
Molecular Omics,
Journal Year:
2024,
Volume and Issue:
20(4), P. 220 - 233
Published: Jan. 1, 2024
This
review
initially
presents
relevant
patient-derived
models,
including
PDXs,
PDOs,
and
PDEs.
Subsequently,
a
comprehensive
summary
of
single-cell
analyses
conducted
on
these
models
is
provided.
Molecular Cancer,
Journal Year:
2023,
Volume and Issue:
22(1)
Published: Nov. 30, 2023
Current
research
has
demonstrated
that
extracellular
vesicles
(EVs)
and
circulating
tumor
cells
(CTCs)
are
very
closely
related
in
the
process
of
distant
metastasis.
Primary
tumors
shed
released
into
bloodstream
to
form
CTCs
referred
as
seeds
colonize
grow
soil-like
target
organs,
while
EVs
nontumor
origin
act
fertilizers
There
is
no
previous
text
provides
a
comprehensive
review
role
on
during
In
this
paper,
we
reviewed
mechanisms
metastasis,
including
ability
enhance
shedding
CTCs,
protect
circulation
determine
direction
CTC
thus
affecting
metastasis
tumors.
Cancer Communications,
Journal Year:
2023,
Volume and Issue:
44(1), P. 3 - 22
Published: Dec. 30, 2023
Abstract
In
recent
years,
remarkable
breakthroughs
have
been
reported
on
antibody‐drug
conjugates
(ADCs),
with
15
ADCs
successfully
entering
the
market
over
past
decade.
This
substantial
development
has
positioned
as
one
of
fastest‐growing
domains
in
realm
anticancer
drugs,
demonstrating
their
efficacy
treating
a
wide
array
malignancies.
Nonetheless,
there
is
still
an
unmet
clinical
need
for
wider
application,
better
efficacy,
and
fewer
side
effects
ADCs.
An
ADC
generally
comprises
antibody,
linker
payload,
combination
profound
drug
structure,
pharmacokinetic
profile
efficacy.
Hence,
optimization
key
components
provides
opportunity
to
develop
higher
potency
effects.
this
review,
we
comprehensively
reviewed
current
prospects
ADC,
provided
analysis
marketed
ongoing
pipelines
globally
well
China,
highlighted
several
platforms
technologies
specific
different
pharmaceutical
enterprises
biotech
companies,
also
discussed
new
related
technologies,
possibility
next‐generation
directions
research.
Experimental Hematology and Oncology,
Journal Year:
2023,
Volume and Issue:
12(1)
Published: Aug. 3, 2023
Organoids
are
established
through
in
vitro
3D
culture,
and
they
can
mimic
the
structure
physiological
functions
of
organs
or
tissues
vivo.
have
attracted
much
attention
recent
years.
They
provide
a
reliable
technology
platform
for
cancer
research
treatment
valuable
preclinical
model
academic
personalized
medicine.
A
number
studies
confirmed
that
organoids
great
application
prospects
new
drug
development,
screening,
tumour
mechanism
research,
precision
In
this
review,
we
mainly
focus
on
advances
research.
We
also
discussed
opportunities
challenges
facing
organoids,
hoping
to
indicate
directions
development
future.
Medicine in Omics,
Journal Year:
2024,
Volume and Issue:
11, P. 100039 - 100039
Published: May 21, 2024
Over
the
last
few
years,
development
of
so-called
omics
technologies
has
greatly
contributed
to
discovery
new
biomarkers
and
targets,
embracing
various
fields
from
diagnostics
therapy
contributing
meliorate
advance
precision
personalized
medicine.
In
addition
classic
omics,
including
genomics,
transcriptomics,
proteomics,
metabolomics,
newer-generation
their
platforms,
such
as
microbiomics
nutrigenomics,
are
emerging.
parallel,
use
liquid
biopsies,
optimal
biological
samples,
consisting
in
fluids
(i.e.
blood,
saliva,
urine)
easy
collect,
whose
components
(cells,
nucleic
acids,
exosome)
can
be
analysed
using
throughput
techniques,
is
becoming
an
attractive,
because
enables
extrapolation
big
data
via
multi-omics
technologies.
Here,
we
report
a
brief
description
discussion
technologies,
by
evidencing
applications
eventual
limitations.
